GlassScriptPhysician profile
Donatella B Graffino
NPI 1952302192
$15,248.49
in general payments reported to CMS, 2019-2025
32 companies · $1,165 in 2025
The $1,165 reported for 2025 was more than what a typical Allergy provider received nationally (typical 2025 total: $1,129).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,110 · 2020: $3,783 · 2021: $3,771 · 2022: $2,502 · 2023: $1,630 · 2024: $1,288 · 2025: $1,165.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,838 · Education: $226 · Consulting Fee: $18.83.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,838.44 |
| Education | $225.50 |
| Consulting Fee | $18.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $7,324.06 | 2019-2025 | Xembify |
| Glaxosmithkline, LLC. | $2,360.54 | 2019-2025 | Trelegy Ellipta, Arexvy, Nucala |
| Genzyme Corporation | $1,575.66 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,489.26 | 2019-2025 | Tezspire, Fasenra, Airsupra |
| Pfizer INC. | $305.14 | 2019-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $278.64 | 2020-2025 | Cuvitru, Hyqvia, Aralast |
| Amgen INC. | $201.90 | 2022-2025 | Tezspire |
| Sanofi-Aventis U.S. LLC | $201.75 | 2022-2025 | |
| Optinose US, INC. | $190.92 | 2019-2022 | |
| Bio Products Laboratory USA, INC. | $167.21 | 2019-2023 | Gammaplex, Coagadex |
| Csl Behring | $143.34 | 2021-2025 | Hizentra |
| Regeneron Healthcare Solutions, INC. | $137.89 | 2019-2024 | Dupixent |
| Alk-Abello, INC | $105.87 | 2019-2023 | Ragwitek, Odactra, Grastek |
| Genentech USA, INC. | $95.45 | 2019-2023 | Xolair |
| Ars Pharmaceuticals Operations, INC. | $82.27 | 2025 | Neffy |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kaleo, INC. | $80.97 | 2022-2024 | Auvi-Q |
| Octapharma USA, INC. | $76.15 | 2020-2024 | Panzyga |
| Incyte Corporation | $68.33 | 2021-2022 | |
| Shire North American Group INC | $53.17 | 2019 | |
| Pharming Healthcare, INC. | $51.31 | 2019-2025 | Ruconest |
| Novartis Pharmaceuticals Corporation | $42.93 | 2025 | |
| Jazz Pharmaceuticals INC. | $42.43 | 2020-2021 | |
| Tersera Therapeutics LLC | $26.45 | 2021 | |
| Axsome Therapeutics, INC. | $20.93 | 2024 | Sunosi |
| Adma Biomanufacturing LLC | $18.83 | 2025 | |
| Biocryst US Sales Co., LLC | $17.50 | 2025 | Orladeyo |
| Harmony Biosciences LLC | $16.76 | 2024 | |
| Organon LLC | $16.71 | 2025 | Vtama |
| Blueprint Medicines Corporation | $16.17 | 2024 | Ayvakit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.42 | 2022 | |
| Mylan Specialty L.P. | $13.13 | 2019 | |
| Eisai INC. | $12.40 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donatella Graffino listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.